Miami, FL Clinical Trials Report — May 2026

For Miami residents interested in contributing to medical research, May 2026 brings both immediate opportunities and significant new studies. With 98 clinical trials in Miami slated to conclude enrollment within the next 90 days, prompt action is essential for those considering participation. Among these, 16 trials are actively seeking healthy volunteers, offering a chance to contribute to science without a specific medical condition before their deadlines pass.

Urgent Opportunities in Key Health Areas

Individuals managing certain health conditions should note the impending deadlines for several trials. Conditions with trials closing soon include:

• Metastatic cancer (3 trials)
• Breast cancer (3 trials)
• Obesity (3 trials)
• Diabetic foot ulcer (DFU) (3 trials)
• Heart failure (3 trials)
• Advanced solid tumor (2 trials)
• HIV infections (2 trials)
• Overweight (2 trials)
• Amyotrophic lateral sclerosis (2 trials)

Additionally, 2 trials specifically for healthy volunteers are among those closing soon, highlighting a time-sensitive opportunity for individuals without specific health conditions to participate.

New Research Horizons in Miami

This month, Miami welcomed 23 new clinical trials, a slight increase from the 22 trials that opened in March 2026. This expansion contributes to Miami's robust research landscape, which currently features 1,299 actively recruiting clinical trials across 832 research facilities. These new studies are predominantly drug trials, with 20 new drug trials, alongside 4 other types of studies, 1 biological, 1 diagnostic test, and 1 procedure trial.

Several high-profile new trials have launched in Miami this May, including significant Phase 3 studies from major sponsors. These offer participants access to cutting-edge treatments and diagnostic approaches for a range of health challenges:

• Novo Nordisk A/S is sponsoring a notable Phase 3 study, NCT07567001, "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims to enroll 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure (with preserved or mildly reduced Ejection Fraction) and excess body weight.
• Another significant Phase 3 trial from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This study plans for 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes.
• AstraZeneca is leading NCT07611110, "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)." This Phase 3 study, targeting 670 participants, aims to demonstrate the superiority of AZD2265 in improving radiographic progression-free survival and overall survival for patients with metastatic castration-resistant prostate cancer.
• Janssen Research & Development, LLC is sponsoring NCT07573176, "A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder." This Phase 3 trial seeks 600 participants to assess the efficacy of the study drug (JNJ-42847922) compared to placebo in improving depressive symptoms in individuals with major depressive disorder.
• Eli Lilly and Company has launched NCT07602582, "A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT)." This Phase 3 study, with 550 participants, aims to determine if participants who previously took donanemab receive clinical benefit from annual doses.
• The University of California, San Francisco is sponsoring NCT07579364, "Outcomes Tracking in Unilateral Vocal Fold Paralysis (UVFP) and Atrophy After Medialization Laryngeal Surgery." This observational study, involving 500 participants, seeks to understand the long-term outcomes of Laryngeal Framework Surgery in patients with Unilateral Vocal Fold Paralysis or Vocal Fold Atrophy.

New trials this month are exploring a range of conditions, with the most frequent being obesity (4 trials), overweight (2 trials), and type 2 diabetes (2 trials). Other conditions include atopic dermatitis, castration-resistant metastatic prostate cancer, and major depressive disorder.

Miami's Leading Research Facilities

Miami is home to prominent research institutions that consistently conduct a high volume of clinical trials, making them key destinations for those looking to participate in medical research:

• University of Miami (229 trials)
• University of Miami Miller School of Medicine-Sylvester Cancer Center (86 trials)
• Nicklaus Children's Hospital (57 trials)
• Miami Cancer Institute (51 trials)
• UM Sylvester Comprehensive Cancer Center at Kendall (35 trials)
• Research Site (32 trials)
• Sylvester Comprehensive Cancer Center (28 trials)
• University of Miami Miller School of Medicine (18 trials)
• Miami Cancer Institute at Baptist Health, Inc. (17 trials)
• University of Miami Hospital (17 trials)
• GSK Investigational Site (16 trials)
• Bascom Palmer Eye Institute (15 trials)

These facilities offer a broad spectrum of research, from oncology at the Sylvester Cancer Centers and Miami Cancer Institute, to pediatric care at Nicklaus Children's Hospital, and diverse medical fields at the University of Miami and its associated medical school.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are numerous opportunities to contribute to research in Miami. Currently, 119 clinical trials are recruiting healthy participants across the city. Of the 23 new trials launched this month, 1 is accepting healthy volunteers, adding to the ongoing options for those interested in supporting medical advancements.

Broadening Your Search: Nearby Florida Cities

While Miami offers a vast array of clinical trial opportunities, individuals may also find options in other communities within Florida. Nearby cities with active trials include Jacksonville (12 trials), Tampa (9 trials), Orlando (9 trials), Gainesville (6 trials), Winter Park (6 trials), Maitland (5 trials), Miami Lakes (4 trials), and Coral Gables (4 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 23 new trials launched this month, 21 include older adults, 1 includes children, 2 are female-only, and 3 are male-only. Industry sponsors like AstraZeneca (4 trials), Eli Lilly and Company (3 trials), and Novo Nordisk A/S (3 trials) are driving significant research efforts in Miami.

As Miami continues to be a hub for medical innovation, the coming months are expected to bring further opportunities for residents to engage with cutting-edge research and contribute to the future of healthcare.